US 11519020
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted A61KA61K2039/505A61K39/001135
Quick answer
US patent 11519020 (Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K39/001135, A61P, A61P27/00